Skip to content

A study of a consensus programme of Chinese and Western medicine interventions in a population with perimenopause-related sleep disturbances

A study of a consensus programme of Chinese and Western medicine interventions in a population with perimenopause-related sleep disturbances

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000921
Enrollment
Unknown
Registered
2025-05-07
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perimenopause-related sleep disturbances

Interventions

Control Group:Zopiclone
Experimental Group two:Zhumian-Tang combined with zopiclone
Experimental Group one:Zhumian-Tang

Sponsors

Sichuan Provincial Hospital of Integrative Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
40 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Female participants aged 40-60 years; (2) Meeting diagnostic criteria for perimenopause as defined by the Stages of Reproductive Aging Workshop (STRAW) staging system; (3) Meeting diagnostic criteria for sleep disturbances as defined by the International Classification of Sleep Disorders 3rd Edition (ICSD-3); (4) Voluntary participation in the clinical trial with provision of written informed consent.

Exclusion criteria

Exclusion criteria: (1)Non-natural menstrual cycle alterations induced by surgical interventions radiotherapy or pharmacological treatments; (2) Sleep disorders secondary to other disease such as obstructive sleep apnea syndrome restless legs syndrome etc; (3) Patients with major depression [Patient Health Questionnaire 9 (PHQ-9) score = 15]; (4) Patients with severe anxiety [Generalised Anxiety Disorder-7 (GAD-7) score = 15]; (5) Recent use of hormone replacement therapy or sleep-modulating pharmacotherapy within 4 weeks prior to enrollment.; (6) Current pregnancy lactation planned conception during the study period or documented psychiatric disorder; (7) Hepatic/renal dysfunction with laboratory values =1.5 times the upper limit of normal (8) Hypersensitivity to the ingredients of the drugs used in this trial (9) Concurrent enrollment in other interventional clinical trials.

Design outcomes

Primary

MeasureTime frame
Pittsburgh Sleep Quality Index (PSQI);

Secondary

MeasureTime frame
Follicle stimulating hormon (FSH);Luteinising hormone (LH);Treatment Emergent Symptom Scale(TESS);Modified Kupperman Index (MKI);Generalised Anxiety Disorder-7 (GAD-7);Estradiol (E2);Patient Health Questionnaire 9 (PHQ-9);

Countries

China

Contacts

Public ContactSunjungang

Sichuan Provincial Hospital of Integrative Medicine

32298854@qq.com15520776262

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026